Amgen on Friday revealed its PCSK9 drug Repatha (evolocumab) reduced the risk of major adverse cardiovascular events but had no effect on cardiovascular death, mixed results which could spell ...

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to ...

Repatha (evolocumab) is a prescription drug used in certain situations to lower cholesterol and reduce serious heart-related risks. Repatha does this by attaching itself to a protein in your body ...

The U.S. Food and Drug Administration today approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL)cholesterol under control with current ...

Pharmaceutical maker Amgen will lower the sticker price of its cholesterol drug Repatha (generic: evolocumab) by 60% to $5,850 a year, it announced Wednesday. Repatha is a PCSK9 inhibitor shown to ...

Amgen has a new tool to employ in its battle with Sanofi and Regeneron for PCSK9 market dominance. The drugmaker said today that the FDA has approved a new hands-free injector for a once-monthly dose ...

Q. I developed severe depression while taking Repatha, the injectable cholesterol lowering drug. It took me a horrible nine months to realize the drug was making me suicidal. If I wasn’t sleeping, I ...

Amgen has presented clinical data indicating that its PCSK9 inhibitor Repatha could help to reverse heart disease by removing atherosclerotic plaques, showing for the first time that the effect of ...

Amgen's cholesterol drug Repatha has a new use in Europe, as the company continues in its battle with Sanofi/Regeneron's rival therapy, Praluent. A PCSK9 inhibitor class drug, Repatha (evolocumab) is ...

It's common for drugmakers to offer behind-the-scenes rebates and discounts to win coverage for their drugs. But cut list prices? That's far more rare. Amgen, though, is doing just that with its PCSK9 ...

For all the talk about new opportunities for consumers to make their own healthcare decisions, much remains out of their control. Nowhere is that more evident than in the prescription drug market, ...